BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

XDx, Inc. 

3260 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-287-2300 Fax: 415-287-2450


SEARCH JOBS


XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non invasive gene expression testing in the areas of transplant medicine and autoimmunity.

The company has developed a proprietary new method of utilizing gene expression that provides additional options for current patient management by physicians specializing in these disease areas.

This work is the basis for AlloMap® Molecular Expression Testing. Performed solely in the XDx Reference Laboratory, the AlloMap test is a service that is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. The AlloMap test may be used for heart transplant recipients 15 years of age or older who are at least 2 months (= 55 days) post-transplant.

The AlloMap molecular expression technology developed and implemented by XDx in heart transplant patient management may be broadly applicable to other diseases that involve the immune system.

Additional information can be found at: www.xdx.com


 Key Statistics


Email:
Ownership: Private

Web Site: XDx, Inc.
Employees:
Symbol: 
 









 Company News
Diaxonhit Agrees to Commercialize in Europe the XDx, Inc. AlloMa® Heart Transplant Test Following the Completion of Exclusive License Agreement 6/27/2013 10:04:21 AM
CML Healthcare Inc. (CLC) and XDx, Inc.Announce Exclusive Licensing Agreement to Market and Distribute AlloMap® Heart Transplant Test 6/20/2013 9:18:42 AM
Diaxonhit and XDx, Inc. Enter Into a Memorandum of Agreement for the Exclusive License to Market and Perform AlloMap® in Europe 6/4/2013 10:23:18 AM
XDx, Inc. Announces Presentations at Upcoming 2013 International Society for Heart and Lung Transplantation Meeting 4/24/2013 9:55:14 AM
XDx, Inc. Announces that Medi-Cal Agrees to Cover AlloMap® for Monitoring Heart Transplant Recipients 3/19/2013 9:21:26 AM
XDx, Inc. Taps Peter Maag as New President and CEO 10/1/2012 7:17:56 AM
Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to XDx, Inc. 9/12/2012 11:39:24 AM
XDx, Inc. and Laboratory Corporation of America Holdings (LabCorp) (LH) Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor Test 5/23/2012 10:47:33 AM
XDx, Inc. Announces Positive Results from European CARGO II Study of AlloMap® Molecular Expression Testing 4/19/2012 10:11:35 AM
XDx, Inc. Launches AlloMap® Molecular Expression Testing in Germany 4/4/2012 9:36:41 AM
123456